Chronic fatigue syndrome biomarkers found

US researchers have identified biomarkers associated with the severity of chronic fatigue syndrome (CFS), which may help lead to a diagnostic blood test. The findings showed evidence that inflammation is a driver of CFS, the underpinnings of which have eluded scientists for decades.

The CFS leads many patients to have flu-like symptoms common in inflammation-driven diseases, while other patients may have symptoms sometimes manifesting as heart problems, mental impairment, indigestion, diarrhoea, constipation, muscle pain, tender lymph nodes, said Jose Montoya, Professor of Infectious Diseases and lead author of the study.

More than one million people in the US suffer from the CFS, also known as myalgic encephalomyelitis. It was reported earlier in 2017 that in Norway, a nation with a population of over five million, about 270 primary and secondary students dropped school due to the syndrome.

The disorder has no known cure or reliably effective treatments. For unknown reasons, the syndrome typically persists for decades, and likely hits among adolescents between the age of 15 and 20, and adults between 30 and 35. Three of every four patients are women.

Antivirals, anti-inflammatories and immune-modulating drugs have led to symptomatic improvement in some cases. However, no single pathogenic agent can be fingered, as the ultimate CFS trigger has yet been isolated, said Montoya.

The findings were published in the Proceedings of the National Academy of Sciences released on July 31. The average age of the patients and controls was about 50, and the patients' average duration of symptoms was more than 10 years.

The authors of the study believe that their findings could improve the diagnosis and treatment of the disorder, including clinical trials to test the potential of immunomodulatory drugs as CFS therapies.